StockWatch
·

HealthCare Global Enterprises Ltd Q2 FY27 Results

HCGQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue731.805.3%13.1%
Total Income733.713.7%13.0%
Expenditure704.633.1%11.8%
PBT17.4927.4%10.3%
Net Profit9.2543.8%55.2%
OPM16.64%0.95pp2.42pp
NPM1.26%1.07pp1.92pp
EPS0.3265.2%72.4%
View full financials

Revenue grew a healthy 13.1% but adjusted net profit fell 55.2% YoY on sharp margin compression (OPM 19.1%→16.6%, NPM 3.2%→1.3%), making this a below-par quarter despite top-line growth.

HEALTHCARE GLOBAL ENTERPRISES · Q2 FY27 · THE VERDICT

13% Revenue, 55% Profit Collapse: The Provision Gap HCG Won't Repeat

Revenue growth is solid and EBITDA is expanding, but reported profit crashed 55%. A ₹116 crore H1 EPCG provision and tax swing explain it — and the company's 'adjusted PAT' narrative sidesteps the real damage of a regulatory headwind arriving next quarter.

09 Nov 2026 · 6 min read
Reported PAT

₹9.3 Cr

-55.2% YoY

EPCG provision (H1)

₹116 Cr

~₹58 Cr Q2 impact

Adjusted PAT (H1)

₹28.7 Cr

+30% YoY claimed

The headline reads like a disaster: profit down 55% despite revenue growing 13%. But the real story sits in two non-cash charges. A ₹116 crore EPCG (export promotion capital goods) provision in H1 and a ₹30 crore swing in tax accounting (deferred asset reversal from ₹99.6 Cr prior year) account for almost all of the PAT miss. Dig past management's 'adjusted' narrative — which claimed 30% H1 PAT growth to soften the GAAP blow — and you find operational profit actually did grow, but the exceptional items are material and front-loaded. The EPCG provision is retroactive and non-cash, so it won't recur, but it distorts the quarter and raises questions about management's transparency on one-time impacts.

The core tension: operational strength vs. reported weakness

Q2 FY27 comparison
0273.21546.41819.62731.8Revenue142.5EBITDA9.3PAT
₹ Cr. Revenue +13.1% and EBITDA +17% show stable operations; PAT -55% is distorted by ₹116 Cr H1 EPCG provision and tax adjustments.

The operating story is cleaner: EBITDA grew 17% and margin held stable at 19.7% (vs 19.2% prior year), confirming that the hospital network is executing well. North Bengaluru's losses narrowed to ₹6 Cr in Q2 (from ₹7.5 Cr in Q1), and the company added 25 operational beds in the quarter as it races toward a ₹520 crore bed expansion over FY28–29. Non-institutional revenue (higher-margin, premium payors) grew 21% and now represents 69% of the total, up from ~60% prior. Patient volumes rose 9% YoY and ARPP (average revenue per patient) grew 7%, both credible metrics for a 13% revenue outturn.

Management's claims vs. what holds up

Five key statements graded against the numbers

Q2 revenue grew 16% on like-for-like basis (excl. Milann divested)

GAAP reported ₹731.8 Cr, +13.1% YoY

Contradicted (3pp miss)

EBITDA margin 19.7%, target 21–22% within 2 years

H1 EBITDA ₹274 Cr at 19.7% margin, stable trajectory

Supported, but new headwind

Adjusted PAT +30% growth H1

H1 adjusted ₹28.7 Cr vs ₹22.1 Cr prior; GAAP Q2 ₹9.3 Cr (−55%)

Overstated (obscures ₹116 Cr EPCG)

North Bengaluru on track to monthly EBITDA breakeven Q4 FY27

Q1 loss ₹7.5 Cr, Q2 loss ₹6 Cr; trajectory reasonable but not yet breakeven

Partial (ramp credible, execution-dependent)

Mid-teens revenue growth maintained; price cap offset via volume & mix

Q2 delivered 13.1% (low end); cap mechanisms untested; volume growth 9%

Conditional (offset not yet proven)

What changed on this call

How the street is positioned

HCG trades at ₹601, down 24.85% from its all-time high of ₹799.7 but up 17.09% off its 52-week low. The stock sits above its 20-day moving average (₹585.44) but below both the 50-day (₹650.14) and 200-day (₹624.51) averages, suggesting near-term support but longer-term uncertainty. RSI of 46.6 signals neutral momentum — no oversold bounce or overbought exhaustion yet. Volume is normal. The drawdown is material but not panic-driven.

Institutional ownership has been flat to slightly negative: FII holdings fell 0.01pp QoQ to 2.74% (down from a high of 3.59% two years ago), signaling consistent foreign fund retreat. DII added 0.29pp to 19.20%, suggesting domestic institutions are holding or nibbling but not accumulating aggressively. Promoter stake is locked at 64.21%, stable. The ownership structure shows no insider selling near the high, but foreign money is still leaving — a warning sign that the regulatory headwind and PAT volatility have dented confidence.

The stock's drawdown from the high is legitimate: price cap risk is new, PAT is volatile, and revenue growth is slower than the narrative suggested. But the absolute level — still 17% above the 52-week low — implies the market hasn't fully priced in either a recovery or a structural margin collapse. That's where the debate lives.

The bull-bear ledger

  • EBITDA +17%, margin stable at 19.7% — operational discipline intact despite regulatory noise

  • Non-institutional revenue +21%, now 69% of mix — deliberate shift to premium, higher-margin payors is working

  • Advanced therapies ramp (robotic surgeries +37% YoY, CAR-T, MR-LINAC) — differentiation in premium oncology segment

  • Reported PAT -55% YoY, leans 59% on provisions and tax adjustments — earnings quality flagged

  • Price cap on 137 oncology drugs effective Q3; offset mechanisms untested — near-term margin headwind real

  • North Bengaluru still loss-making ₹6 Cr Q2; path to breakeven Q4 credible but extends PAT drag

  • Revenue growth 13.1% vs claimed 16% — topline narrative softer than presentation

Ranked risks for a holder

What should concern an HCG shareholder, most material first

Price cap on oncology drugs (₹137 drug list, 30% margin cap effective Q3)

High

Mid-to-high single-digit EBITDA headwind annually on annualized basis. Offset mechanisms (volume, mix, efficiency) are real but untested under regulatory pressure. If volumes compress due to affordability concerns or payor shifts, margin compression could exceed guidance. Q3 earnings will be the first test.

PAT volatility from one-time charges (EPCG ₹116 Cr H1, tax swings)

High

GAAP PAT collapsed 55% despite operational strength. Management's 'adjusted PAT' narrative suggests limited transparency on exceptional items. Tax normalization is expected post-clarity on deferred assets, but if further provisions emerge, investor confidence in reported profits erodes further.

North Bengaluru ramp-up losses extending beyond Q4

Medium

Hospital targeting monthly EBITDA breakeven by Q4 FY27 (Jan–Mar quarter). Losses narrowed ₹7.5 Cr → ₹6 Cr but still material. Any delay extends PAT drag into FY28 and raises execution risk on capex productivity. Network synergy claims need validation.

Revenue growth deceleration: 13.1% delivered vs 16% claimed

Medium

3pp gap suggests either lower underlying growth trajectory or persistent institutional payor mix headwinds. If institutional pullback continues and non-institutional growth slows, mid-teens guidance becomes a ceiling, not a floor.

Geopolitical headwinds on MVT (Medical Value Travel) — 4–5% of revenue, +25% growth but exposed

Low

MVT growing at 25% YoY but management cited Middle East and Bangladesh disruptions offsetting growth. Diversification (Kenya, Kolkata, Nagpur) underway but visibility on sustainability of 25% growth unclear if geopolitical shocks repeat.

The debate

What to watch next

  • 1 · Q3 FY27 EBITDA impact from price cap regulation

    Management estimated mid-to-high single-digit EBITDA headwind. Q3 is the first full quarter after the cap takes effect (November 2026). Actual results will show whether volume growth (+9% Q2), ARPP trends (+7% Q2), and mix improvement (non-institutional +21%) are strong enough to offset. EBITDA margin compression vs 19.7% Q2 will signal success or warning.

  • 2 · North Bengaluru monthly EBITDA breakeven by Q4 FY27

    Hospital targeting Jan–Mar 2027 monthly breakeven. If achieved, it validates the ramp trajectory and provides visibility into FY28 PAT recovery (no more quarterly losses). Delay or further losses extend the margin/profit drag. Watch for commentary on infrastructure utilization, patient volumes, and ARPP at the new facility.

  • 3 · Adjusted vs GAAP PAT reconciliation and tax normalization

    Q3 will show whether PAT recovers toward the adjusted run-rate (~₹28.7 Cr H1 adjusted) or remains depressed. If new provisions or tax swings emerge, management's credibility on 'adjusted' metrics will erode. Watch for clarity on deferred asset realization timing and any further EPCG or exceptional items.

The single number to track

Adjusted EBITDA margin Q3 FY27. This quarter, it was 19.7%. Price cap regulations hit in Q3. If adjusted EBITDA margin (stripping out one-time items) stays at 19.7% or rises toward 20%, the company has proven it can offset the headwind. If it compresses to 19% or below, the bearish case (structural margin pressure, offset mechanisms failing) takes hold. That's the line in the sand for whether mid-teens revenue growth translates to margin expansion or margin defense.

HCG delivered a quarter that looks worse on paper than it is in reality — operational EBITDA is solid, the network is executing, and advanced therapies are differentiating the company in premium segments. But the stock's 24% drawdown from the all-time high is earned: reported profit collapsing 55% (even with good reasons), a new regulatory margin cap taking effect next quarter, and management's on-call optics (the 'adjusted' narrative) raising flags about transparency. This is not a crisis, but it's a compression cycle. The company enters a 2–3 quarter testing ground where assumptions about North Bengaluru breakeven, price cap resilience, and volume/mix offsets get validated or not. For holders, patience through Q3–Q4 is warranted; patience is not the same as complacency. For potential buyers, wait for Q3 price-cap proof points before re-rating up. Steady execution, not a step-change. Watch adjusted EBITDA margin; that's the tiebreaker.

Informational and educational content only. Not investment advice.